Researchers who used PET found that sugar uptake changes between baseline and two weeks after the start of pertuzumab and trastuzumab treatment without chemotherapy yielded high sensitivity and very high negative predictive value in predicting treatment response among women with stage II or stage III ER-negative, HER2-positive breast cancer, with those having elevated sugar levels post-treatment likely to need chemotherapy. The findings in the Journal of Clinical Oncology may prompt better-targeted breast cancer treatments, but more studies are needed before widespread use of the PET scan biomarker, researcher Dr. Vered Stearns said.
Study: PET procedure can predict if chemo is needed in breast cancer
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.